Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.41 |
| ▸ | WNT1 | P04628 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 10/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | CLK3 | P49761 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774068 | 0.95 | DYRK1A (0.39) | DYRK1AWNT1PIM1 | |
| SCHEMBL5775521 | 0.86 | DYRK1A (0.55) | DYRK1AWNT1PIM1KDM4EALDH1A1 | |
| SCHEMBL5795447 | 0.84 | PIM1 (0.41) | DYRK1APIM1CLK2CLK3ALDH1A1 | |
| SCHEMBL5775974 | 0.84 | ATAD2 (0.40) | DYRK1AWNT1KDM4EALDH1A1MAPT | |
| SCHEMBL5873102 | 0.83 | DYRK1A (0.49) | DYRK1AWNT1PIM1 | |
| SCHEMBL5770580 | 0.82 | CDC7 (0.47) | KDM4EALDH1A1MAPT | |
| SCHEMBL5747881 | 0.81 | KDM4E (0.45) | DYRK1AWNT1PIM1KDM4EALDH1A1 | |
| SCHEMBL5872880 | 0.80 | CYP2C9 (0.43) | PIM1ALDH1A1 | |
| SCHEMBL5770048 | 0.80 | PIM1 (0.43) | PIM1 | |
| SCHEMBL5769674 | 0.80 | PIM1 (0.40) | PIM1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664040-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| WO-2005026162-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | DYRK1A 1836/4885WNT1 3712/4885PIM1 1909/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | DYRK1A 1836/4885WNT1 3712/4885PIM1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.